Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study

JR Valdizán-Usón,1 A Cánovas-Martínez,2 MT De Lucas-Taracena,3 F Díaz-Atienza,4 LS Eddy-Ives,5 A Fernández-Jaén,6 M Fernández-Pérez,7 M García-Giral,8...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Valdizán-Usón JR, Cánovas-Martínez A, De Lucas-Taracena M, Díaz-Atienza F, Eddy-Ives LS, Fernández-Jaén A, Fernández-Pérez M, García-Giral M, García-Magán P, Garraus-Oneca M, Idiazábal-Alecha MA, López-Benito M, Lorenzo-Sanz G, Martínez-Antón J, Martínez-Granero MA, Montañés-Rada F, Mulas-Delgado F, Ochando-Perales G, Ortega-García E, Pelaz-Antolín A, Ramos-Quiroga JA, Ruiz-Sanz FC, Vaquerizo-Madrid J, Yusta-Izquierdo A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://doaj.org/article/8b681678684c4f41861cbfafc5e7256b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8b681678684c4f41861cbfafc5e7256b
record_format dspace
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Valdizán-Usón JR
Cánovas-Martínez A
De Lucas-Taracena M
Díaz-Atienza F
Eddy-Ives LS
Fernández-Jaén A
Fernández-Pérez M
García-Giral M
García-Magán P
Garraus-Oneca M
Idiazábal-Alecha MA
López-Benito M
Lorenzo-Sanz G
Martínez-Antón J
Martínez-Granero MA
Montañés-Rada F
Mulas-Delgado F
Ochando-Perales G
Ortega-García E
Pelaz-Antolín A
Ramos-Quiroga JA
Ruiz-Sanz FC
Vaquerizo-Madrid J
Yusta-Izquierdo A
Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
description JR Valdizán-Usón,1 A Cánovas-Martínez,2 MT De Lucas-Taracena,3 F Díaz-Atienza,4 LS Eddy-Ives,5 A Fernández-Jaén,6 M Fernández-Pérez,7 M García-Giral,8 P García-Magán,9 M Garraus-Oneca,10 MA Idiazábal-Alecha,11 M López-Benito,12 G Lorenzo-Sanz,13 J Martínez-Antón,14 MA Martínez-Granero,15 F Montañés-Rada,16 F Mulas-Delgado,17 G Ochando-Perales,18 E Ortega-García,19 A Pelaz-Antolín,20 JA Ramos-Quiroga,21 FC Ruiz-Sanz,22 J Vaquerizo-Madrid,23 A Yusta-Izquierdo241Unidad Trastornos Neurofuncionales, Clínica Montpellier, Zaragoza, 2Hospital Dr Peset, Valencia, 3Hospital 12 de Octubre, Madrid, 4Hospital Virgen de las Nieves, Granada, 5Centre Mèdic Sant Ramon, Santa Coloma de Gramenet, Barcelona, 6Hospital Universitario Quirón, Madrid, 7Centro de Salud La Felguera, Langreo, Asturias, 8Hospital Clínic, Barcelona, 9Unidad Salud Mental, Talavera de la Reina, 10Clínica Universitaria de Navarra, Pamplona, 11Hospital Ntra. Sra. del Pilar, Barcelona, 12Centro Salud Contrueces, Gijón, 13Hospital Ramón y Cajal, Madrid, 14Complejo Hospitalario Carlos Haya, Málaga, 15Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 16Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 17Hospital Universitario La Fe, Valencia, 18Hospital Universitario La Fe, Valencia, 19Complejo Asistencial Universitario de León, 20Centro Salud Mental, Alcalá de Henares, 21Hospital Universitari Vall d'Hebron. CIBERSAM. Department of Psychiatry and Legal Medicine. Universitat Autònoma de Barcelona, 22Hospital General Rio Carrión, Palencia, 23Hospital Materno-Infantil, Badajoz, 24Hospital Universitario, Guadalajara, SpainBackground: The purpose of this multicenter Spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivity disorder (ADHD), as well as to obtain information on current therapy patterns and safety characteristics.Methods: This multicenter, observational, retrospective, noninterventional study included 730 patients aged 4–65 years with a diagnosis of ADHD. Information was obtained based on a review of medical records for the years 2002–2006 in sequential order.Results: The ADHD predominantly inattentive subtype affected 29.7% of patients, ADHD predominantly hyperactive-impulsive was found in 5.2%, and the combined subtype in 65.1%. Overall, a significant lower Clinical Global Impression (CGI) score and mean number of DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision) symptoms by subtype were found after one year of treatment with immediate-release methylphenidate; CGI decreased from 4.51 to 1.69, symptoms of inattention from 7.90 to 4.34, symptoms of hyperactivity from 6.73 to 3.39, and combined subtype symptoms from 14.62 to 7.7. Satisfaction with immediate-release methylphenidate after one year was evaluated as “very satisfied” or “satisfied” by 86.90% of the sample; 25.75% of all patients reported at least one adverse effect. At the end of the study, 41.47% of all the patients treated with immediate-release methylphenidate were still receiving it, with a mean time of 3.80 years on therapy.Conclusion: Good efficacy and safety results were found for immediate-release methylphenidate in patients with ADHD.Keywords: attention deficit hyperactivity disorder, ADHD, pharmacologic treatment, methylphenidate, satisfaction
format article
author Valdizán-Usón JR
Cánovas-Martínez A
De Lucas-Taracena M
Díaz-Atienza F
Eddy-Ives LS
Fernández-Jaén A
Fernández-Pérez M
García-Giral M
García-Magán P
Garraus-Oneca M
Idiazábal-Alecha MA
López-Benito M
Lorenzo-Sanz G
Martínez-Antón J
Martínez-Granero MA
Montañés-Rada F
Mulas-Delgado F
Ochando-Perales G
Ortega-García E
Pelaz-Antolín A
Ramos-Quiroga JA
Ruiz-Sanz FC
Vaquerizo-Madrid J
Yusta-Izquierdo A
author_facet Valdizán-Usón JR
Cánovas-Martínez A
De Lucas-Taracena M
Díaz-Atienza F
Eddy-Ives LS
Fernández-Jaén A
Fernández-Pérez M
García-Giral M
García-Magán P
Garraus-Oneca M
Idiazábal-Alecha MA
López-Benito M
Lorenzo-Sanz G
Martínez-Antón J
Martínez-Granero MA
Montañés-Rada F
Mulas-Delgado F
Ochando-Perales G
Ortega-García E
Pelaz-Antolín A
Ramos-Quiroga JA
Ruiz-Sanz FC
Vaquerizo-Madrid J
Yusta-Izquierdo A
author_sort Valdizán-Usón JR
title Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
title_short Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
title_full Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
title_fullStr Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
title_full_unstemmed Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
title_sort response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the spanish multicenter dihana study
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/8b681678684c4f41861cbfafc5e7256b
work_keys_str_mv AT valdizampaacutenusampoacutenjr responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT campaacutenovasmartampiacuteneza responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT delucastaracenam responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT dampiacuteazatienzaf responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT eddyivesls responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT fernampaacutendezjaampeacutena responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT fernampaacutendezpampeacuterezm responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT garcampiacuteagiralm responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT garcampiacuteamagampaacutenp responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT garrausonecam responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT idiazampaacutebalalechama responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT lampoacutepezbenitom responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT lorenzosanzg responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT martampiacutenezantampoacutenj responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT martampiacutenezgraneroma responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT montaampntildeampeacutesradaf responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT mulasdelgadof responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT ochandoperalesg responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT ortegagarcampiacuteae responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT pelazantolampiacutena responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT ramosquirogaja responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT ruizsanzfc responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT vaquerizomadridj responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
AT yustaizquierdoa responsetomethylphenidatebyadultandpediatricpatientswithattentiondeficithyperactivitydisorderthespanishmulticenterdihanastudy
_version_ 1718401503049285632
spelling oai:doaj.org-article:8b681678684c4f41861cbfafc5e7256b2021-12-02T04:02:35ZResponse to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study1176-63281178-2021https://doaj.org/article/8b681678684c4f41861cbfafc5e7256b2013-02-01T00:00:00Zhttp://www.dovepress.com/response-to-methylphenidate-by-adult-and-pediatric-patients-with-atten-a12163https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021JR Valdizán-Usón,1 A Cánovas-Martínez,2 MT De Lucas-Taracena,3 F Díaz-Atienza,4 LS Eddy-Ives,5 A Fernández-Jaén,6 M Fernández-Pérez,7 M García-Giral,8 P García-Magán,9 M Garraus-Oneca,10 MA Idiazábal-Alecha,11 M López-Benito,12 G Lorenzo-Sanz,13 J Martínez-Antón,14 MA Martínez-Granero,15 F Montañés-Rada,16 F Mulas-Delgado,17 G Ochando-Perales,18 E Ortega-García,19 A Pelaz-Antolín,20 JA Ramos-Quiroga,21 FC Ruiz-Sanz,22 J Vaquerizo-Madrid,23 A Yusta-Izquierdo241Unidad Trastornos Neurofuncionales, Clínica Montpellier, Zaragoza, 2Hospital Dr Peset, Valencia, 3Hospital 12 de Octubre, Madrid, 4Hospital Virgen de las Nieves, Granada, 5Centre Mèdic Sant Ramon, Santa Coloma de Gramenet, Barcelona, 6Hospital Universitario Quirón, Madrid, 7Centro de Salud La Felguera, Langreo, Asturias, 8Hospital Clínic, Barcelona, 9Unidad Salud Mental, Talavera de la Reina, 10Clínica Universitaria de Navarra, Pamplona, 11Hospital Ntra. Sra. del Pilar, Barcelona, 12Centro Salud Contrueces, Gijón, 13Hospital Ramón y Cajal, Madrid, 14Complejo Hospitalario Carlos Haya, Málaga, 15Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 16Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 17Hospital Universitario La Fe, Valencia, 18Hospital Universitario La Fe, Valencia, 19Complejo Asistencial Universitario de León, 20Centro Salud Mental, Alcalá de Henares, 21Hospital Universitari Vall d'Hebron. CIBERSAM. Department of Psychiatry and Legal Medicine. Universitat Autònoma de Barcelona, 22Hospital General Rio Carrión, Palencia, 23Hospital Materno-Infantil, Badajoz, 24Hospital Universitario, Guadalajara, SpainBackground: The purpose of this multicenter Spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivity disorder (ADHD), as well as to obtain information on current therapy patterns and safety characteristics.Methods: This multicenter, observational, retrospective, noninterventional study included 730 patients aged 4–65 years with a diagnosis of ADHD. Information was obtained based on a review of medical records for the years 2002–2006 in sequential order.Results: The ADHD predominantly inattentive subtype affected 29.7% of patients, ADHD predominantly hyperactive-impulsive was found in 5.2%, and the combined subtype in 65.1%. Overall, a significant lower Clinical Global Impression (CGI) score and mean number of DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision) symptoms by subtype were found after one year of treatment with immediate-release methylphenidate; CGI decreased from 4.51 to 1.69, symptoms of inattention from 7.90 to 4.34, symptoms of hyperactivity from 6.73 to 3.39, and combined subtype symptoms from 14.62 to 7.7. Satisfaction with immediate-release methylphenidate after one year was evaluated as “very satisfied” or “satisfied” by 86.90% of the sample; 25.75% of all patients reported at least one adverse effect. At the end of the study, 41.47% of all the patients treated with immediate-release methylphenidate were still receiving it, with a mean time of 3.80 years on therapy.Conclusion: Good efficacy and safety results were found for immediate-release methylphenidate in patients with ADHD.Keywords: attention deficit hyperactivity disorder, ADHD, pharmacologic treatment, methylphenidate, satisfactionValdizán-Usón JRCánovas-Martínez ADe Lucas-Taracena MDíaz-Atienza FEddy-Ives LSFernández-Jaén AFernández-Pérez MGarcía-Giral MGarcía-Magán PGarraus-Oneca MIdiazábal-Alecha MALópez-Benito MLorenzo-Sanz GMartínez-Antón JMartínez-Granero MAMontañés-Rada FMulas-Delgado FOchando-Perales GOrtega-García EPelaz-Antolín ARamos-Quiroga JARuiz-Sanz FCVaquerizo-Madrid JYusta-Izquierdo ADove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 211-218 (2013)